Breaking Bone News!

During the course of my work day, I will review and report a large number of chest, spine, or extremity x-rays taken on postmenopausal women with low bone density or osteoporosis. While catching up on journal reading, I came across some exciting research news for women with osteoporosis. Published in the New England Journal of Medicine, a phase 2 trial performed by Amgen and UCB showed that compared to placebo, Romosozumab treatment for 12 months increased bone density at the lumbar spine, total hip and femoral neck. Significant increases were noted in the first BMD test at three-month follow-up. The lumbar spine and hip bone density values were significantly greater than those observed with other treatments such as Fosamax and Forteo. At the end of 12 months of treatment, increase in bone density was 11.3% for Romosozumab at the lumbar